Q-omics provides the consensus-scored LSMEM2 profile across patient tissues and cancer cell-line models. LSMEM2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LSMEM2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LSMEM2 RNA expression shows 17,179 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, KIRC, and ACC as cancer lineages where LSMEM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LSMEM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LSMEM2 survival associations across molecular data types. LSMEM2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LSMEM2 RNA expression–survival associations across cancer types. High LSMEM2 expression shows unfavorable associations in ACC, LUSC and LUAD, but favorable associations in SKCM, BRCA and UVM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LSMEM2 RNA expression.
This table summarizes LSMEM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LSMEM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LSMEM2 shows lower tumor expression in KIRC, KICH, THCA, BLCA, HNSC and KIRP. The KIRC box plot shows higher LSMEM2 RNA expression in normal versus tumor tissue (log2 FC = −0.500, t-test p < 0.001).
This table shows molecular features associated with LSMEM2 in patient tissues and cancer cell lines. In patient samples, LSMEM2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LSMEM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
